Results 71 to 80 of about 4,707 (174)

Efficacy and Safety of Intravenous Tenecteplase Before Endovascular Thrombectomy for Acute Ischemic Stroke: The Multicenter, Randomized, BRIDGE‐TNK Trial Protocol

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Six randomized trials have not detected a difference between intravenous alteplase plus endovascular thrombectomy and endovascular thrombectomy alone in stroke.
Zhongming Qiu, Fengli Li, Dongjing Xie, Guangxiong Yuan, Thanh N. Nguyen, Kai Zhou, Raul G. Nogueira, Jeffrey L. Saver, Bruce C.V. Campbell, Gregory W. Albers, Hongfei Sang, Linyu Li, Yan Tian, Zhaoyou Meng, Duolao Wang, Wenjie Zi, Qingwu Yang   +16 more
doaj   +1 more source

Tenecteplase versus alteplase in elderly stroke: a post hoc analysis of the AcT trial

Stroke and Vascular Neurology
Background Stroke rates rise steeply with age but data on tenecteplase in patients ≥80 years remain limited. This post-hoc analysis of the AcT trial compared tenecteplase with alteplase in this population.Methods The analysis included all Alteplase ...
Mohammed A Almekhlafi, Tolulope Sajobi, Richard H Swartz, Aleksander Tkach, Brian Buck, Nishita Singh, Bijoy Menon, Luciana Catanese, Taha Aslan, Mohamed AlShamrani   +9 more
doaj   +1 more source

Ethnic Differences in the Safety and Efficacy of Tenecteplase Versus Alteplase for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis [PDF]

Journal of Stroke
Background and Purpose Tenecteplase is a thrombolytic agent with pharmacological advantages over alteplase and has been shown to be noninferior to alteplase for acute ischemic stroke in randomized trials.
Jin Hean Koh, Claire Yi Jia Lim, Lucas Tze Peng Tan, Ching-Hui Sia, Kian Keong Poh, Vijay Kumar Sharma, Leonard Leong Litt Yeo, Andrew Fu Wah Ho, Teddy Wu, William Kok-Fai Kong, Benjamin Yong Qiang Tan   +10 more
doaj   +1 more source

Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database

Neurotherapeutics
The angioedema risk may vary among stroke patients receiving different thrombolytic agents. This study aimed to investigate the angioedema risk associated with different thrombolytic agents and to identify associated risk factors.
Hunong Xiang, Yu Ma, Xiaochao Luo, Jian Guo, Minghong Yao, Yanmei Liu, Ke Deng, Xin Sun, Ling Li   +8 more
doaj   +1 more source

Tenecteplase in ischemic stroke offers improved recanalization: analysis of 2 trials

, 2017
Objective: To test whether patients with complete vessel occlusion show greater recanalization at 24 hours and have improved clinical outcomes at 24 hours and 90 days when treated with tenecteplase compared to alteplase.
Moreton, Fiona Catherine, Donnan, Geoffrey A., Fiona Catherine Moreton, Andrew Bivard, Bharath Kumar Cheripelli, Bladin, Christopher F., Bivard, Andrew, Ian Ford, Bruce C.V. Campbell, Huang, Xuya, Neil Spratt, Christopher R. Levi, Keith W. Muir, Campbell, Bruce C.V., Mark W. Parsons, Campbell, Bruce C. V., Cheripelli, Bharath Kumar, Levi, Christopher (R19066), Davis, Stephen M., Xuya Huang, Levi, Christopher R., Geoffrey A. Donnan, Kalladka, Dheeraj, Stephen M. Davis, Parsons, Mark W., Dheeraj Kalladka, Ford, Ian, Christopher F. Bladin, Spratt, Neil, Muir, Keith W.   +29 more
core   +1 more source

Spinal subdural hematoma as a complication of tenecteplase treatment for acute ischemic stroke: A case report

Heliyon
Intravenous thrombolysis is an effective treatment for acute ischemic stroke. The ESO recommends that tenecteplase be used for thrombolytic therapy in stroke within 4.5h of onset.
Sisi Zhao, Lingtao Tang, Yanpeng Lu, Yingyi Li   +3 more
doaj   +1 more source

Efficacy and Safety of Intravenous Tenecteplase Versus Alteplase in Treating Acute Ischemic Stroke With Diabetes and Admission Hyperglycemia

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The aim of this study was to investigate the efficacy and safety of tenecteplase versus alteplase in patients with acute ischemic stroke, considering their diabetes history and admission hyperglycemia status.
Huihui Liu, Aoming Jin, Yuesong Pan, Xia Meng, Hao Li, Zixiao Li, Yongjun Wang, Shuya Li   +7 more
doaj   +1 more source

Safety and Efficacy of Tenecteplase in Comparison with Thrombectomy in Ischemic Stroke [PDF]

, 2019
BACKGROUND: According to the World Health Organization (WHO), it is the second leading cause of death and people above the age of 60 years. Ischemic stroke is a major health problem and leading cause of death and disability.
Mohanapriya, R
core  

Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: a single-center analysis

Frontiers in Neurology
BackgroundThis retrospective observational cohort study aimed to evaluate whether tenecteplase’s use for acute ischemic stroke (AIS) has time management advantages and clinical benefits.Methods144 AIS patients treated with alteplase and 120 with ...
Yu Yao, Yuefei Wu, Xiaoqin Zhang, Chang Liu, Lingling Cai, Yisha Ying, Jianhong Yang   +6 more
doaj   +1 more source

Tenecteplase vs Reteplase in Patients with Acute ST-Elevation Myocardial Infarction: A Retrospective Cohort Study

Clinical and Applied Thrombosis/Hemostasis
Coronary artery disease is one of the leading causes of death globally. Despite the increased number of percutaneous coronary intervention (PCI) capable facilities, fibrinolytic therapy is still being utilized especially in rural areas.
Adham Mohamed PharmD, Sara Mahmoud PharmD, Amr M. Fahmi PhD, Ahmed Mahfouz MSc, Tayseer Kanaan MD, Jihad Jaber MD, Mansour Alkhawi MD, Saleh Alkhalaf MD, Hassan Kodimi MD, Ahmed Shaaban MD, Omar Alshibli MD, Awad Almasalmeh MD, Salaheddin Arafa MD, Salah Elbdri MD, Suhail Falah MD, Fayez Altrad MD, Ezeldin Soaly MD, Rasha Elenany PharmD, Sumaya Alyafei PharmD, Abdul Rahman Arabi MD   +19 more
doaj   +1 more source